• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Monoclonal immunoglobulin measurement by mass spectrometry in patients with multiple myeloma and kidney failure: Analysis from the EuLITE trial.

作者信息

McIlroy Graham, Giles Hannah V, Rollins Amy, Malin Gemma, Jones Libby, Wright Nicola J, Berlanga Oscar, North Simon, Cook Mark, Hutchison Colin, Heyne Nils, Weisel Katja, Pinney Jennifer, Harding Stephen, Cockwell Paul, Pratt Guy

机构信息

University of Birmingham, Birmingham, UK.

University Hospitals Birmingham, Birmingham, UK.

出版信息

Br J Haematol. 2025 May 25;207(1):294-8. doi: 10.1111/bjh.20168.

DOI:10.1111/bjh.20168
PMID:40415308
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12234270/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e0/12234270/20cfce5e1280/BJH-207-294-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e0/12234270/20cfce5e1280/BJH-207-294-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e0/12234270/20cfce5e1280/BJH-207-294-g001.jpg

相似文献

1
Monoclonal immunoglobulin measurement by mass spectrometry in patients with multiple myeloma and kidney failure: Analysis from the EuLITE trial.采用质谱法对多发性骨髓瘤合并肾衰竭患者进行单克隆免疫球蛋白测定：来自EuLITE试验的分析
Br J Haematol. 2025 May 25;207(1):294-8. doi: 10.1111/bjh.20168.
2
Renal Failure-Related Mortality in Multiple Myeloma: United States Trends From 1999 to 2020.多发性骨髓瘤中与肾衰竭相关的死亡率：1999年至2020年美国的趋势
Clin Lymphoma Myeloma Leuk. 2025 Jun 6. doi: 10.1016/j.clml.2025.06.002.
3
A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence?硼替佐米在伴有肾功能损害的多发性骨髓瘤患者中的应用：有哪些已发表的证据？
Acta Haematol. 2011;126(3):163-8. doi: 10.1159/000328417. Epub 2011 Jul 21.
4
Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines.碘对比剂、多发性骨髓瘤和单克隆丙种球蛋白病：文献回顾与 ESUR 对比剂安全委员会指南。
Eur Radiol. 2018 Feb;28(2):683-691. doi: 10.1007/s00330-017-5023-5. Epub 2017 Aug 30.
5
Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.慢性肾脏病与替尔泊肽对射血分数保留的肥胖心力衰竭患者的影响：SUMMIT试验
J Am Coll Cardiol. 2025 May 13;85(18):1721-1735. doi: 10.1016/j.jacc.2025.03.009. Epub 2025 Mar 31.
6
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.仑伐替尼联合帕博利珠单抗治疗未经治疗的晚期肾细胞癌：系统评价和成本效果分析。
Health Technol Assess. 2024 Aug;28(49):1-190. doi: 10.3310/TRRM4238.
7
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial.isatuximab、硼替佐米、来那度胺与小剂量地塞米松用于不适宜移植的多发性骨髓瘤患者（REST）：一项多中心、单臂、2期试验
Lancet Haematol. 2025 Feb;12(2):e120-e127. doi: 10.1016/S2352-3026(24)00347-8.
8
Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy.用于鉴定膜性肾病中靶抗原的数据非依赖型采集质谱分析
Am J Kidney Dis. 2025 Mar 7. doi: 10.1053/j.ajkd.2025.01.014.
9
The Mayo MGRS Prediction Tool calculates the risk of finding monoclonal gammopathy of renal significance in a kidney biopsy in patients with monoclonal gammopathy.梅奥MGRS预测工具可计算单克隆丙种球蛋白病患者肾活检中发现具有肾意义的单克隆丙种球蛋白病的风险。
Kidney Int. 2025 May 20. doi: 10.1016/j.kint.2025.04.018.
10
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.欧洲血液学年会-欧洲骨髓瘤网络关于多发性骨髓瘤患者诊断、治疗及随访的循证指南
Nat Rev Clin Oncol. 2025 Jul 7. doi: 10.1038/s41571-025-01041-x.

本文引用的文献

1
Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry.多发性骨髓瘤患者 IFE 转阴与质谱法检测到残留单克隆游离轻链（FLC）相关，其与无进展生存期相关。
Blood Cancer J. 2024 Mar 18;14(1):50. doi: 10.1038/s41408-024-00995-y.
2
Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis.轻链型淀粉样变性的完全缓解并不相同：游离轻链质谱分析在轻链型淀粉样变性中的影响
Blood. 2024 Mar 28;143(13):1259-1268. doi: 10.1182/blood.2023022399.
3
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study.
定义慢性肾脏病患者血清游离轻链的新参考区间：iStopMM 研究结果。
Blood Cancer J. 2022 Sep 14;12(9):133. doi: 10.1038/s41408-022-00732-3.
4
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.质谱分析与免疫固定电泳在多发性骨髓瘤治疗监测中的比较。
Blood Adv. 2022 Jun 14;6(11):3234-3239. doi: 10.1182/bloodadvances.2021006762.
5
Redefining nonmeasurable multiple myeloma using mass spectrometry.利用质谱法重新定义不可测量的多发性骨髓瘤。
Blood. 2022 Feb 10;139(6):946-950. doi: 10.1182/blood.2021013794.
6
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.质谱法评估多发性骨髓瘤和相关疾病中的单克隆蛋白：国际骨髓瘤工作组质谱学委员会报告。
Blood Cancer J. 2021 Feb 1;11(2):24. doi: 10.1038/s41408-021-00408-4.
7
High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial.高截流与高通量血液透析治疗接受硼替佐米化疗患者的骨髓瘤管型肾病（EuLITE）：一项2期随机对照试验
Lancet Haematol. 2019 Apr;6(4):e217-e228. doi: 10.1016/S2352-3026(19)30014-6. Epub 2019 Mar 11.
8
A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis.一种用于鉴定系统性轻链淀粉样变性中血清单克隆轻链成分的新型质谱方法。
Blood Cancer J. 2019 Feb 4;9(2):16. doi: 10.1038/s41408-019-0180-1.
9
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
10
Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.血清游离轻链的早期降低与骨髓瘤肾的肾功能恢复相关。
J Am Soc Nephrol. 2011 Jun;22(6):1129-36. doi: 10.1681/ASN.2010080857. Epub 2011 Apr 21.